DrugPatentWatch Database Preview
Cubist Pharms Company Profile
What is the competitive landscape for CUBIST PHARMS, and what generic alternatives to CUBIST PHARMS drugs are available?
CUBIST PHARMS has six approved drugs.
There are twenty-one US patents protecting CUBIST PHARMS drugs.
Summary for Cubist Pharms
| US Patents: | 21 |
| Tradenames: | 6 |
| Ingredients: | 5 |
| NDAs: | 6 |
Drugs and US Patents for Cubist Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cubist Pharms Llc | CUBICIN RF | daptomycin | POWDER;INTRAVENOUS | 021572-003 | Jul 6, 2016 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | |||||
| Cubist Pharms Llc | SIVEXTRO | tedizolid phosphate | POWDER;INTRAVENOUS | 205436-001 | Jun 20, 2014 | RX | Yes | Yes | 7,816,379 | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Cubist Pharms | ENTEREG | alvimopan | CAPSULE;ORAL | 021775-001 | May 20, 2008 | RX | Yes | Yes | 8,112,290 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Cubist Pharms Llc | SIVEXTRO | tedizolid phosphate | POWDER;INTRAVENOUS | 205436-001 | Jun 20, 2014 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | |||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for Cubist Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Cubist Pharms | ENTEREG | alvimopan | CAPSULE;ORAL | 021775-001 | May 20, 2008 | 5,250,542 | ➤ Sign Up |
| Cubist Pharms Llc | CUBICIN | daptomycin | POWDER;IV (INFUSION) | 021572-001 | Sep 12, 2003 | RE39071 | ➤ Sign Up |
| Cubist Pharms Llc | CUBICIN | daptomycin | POWDER;INTRAVENOUS | 021572-002 | Sep 12, 2003 | RE39071 | ➤ Sign Up |
| Cubist Pharms Llc | CUBICIN | daptomycin | POWDER;IV (INFUSION) | 021572-001 | Sep 12, 2003 | 5,912,226 | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for CUBIST PHARMS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 200 mg | ➤ Subscribe | 2015-05-27 |
| ➤ Subscribe | For Injection | 500 mg/vial | ➤ Subscribe | 2008-11-19 |
| ➤ Subscribe | Capsules | 12 mg | ➤ Subscribe | 2017-06-16 |
International Patents for Cubist Pharms Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Philippines | 12014500092 | ➤ Sign Up |
| Germany | 60042282 | ➤ Sign Up |
| New Zealand | 718365 | ➤ Sign Up |
| Costa Rica | 20110464 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Cubist Pharms Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 2015032 | Lithuania | ➤ Sign Up | PRODUCT NAME: TEDIZOLIDO FOSFATAS; REGISTRATION NO/DATE: EU/1/15/991 20150323 |
| 2015 00048 | Denmark | ➤ Sign Up | PRODUCT NAME: TEDIZOLID, OPTIONALLY IN THE FORM OF AN ESTER, IN PARTICULAR A PHOSPHATE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING TEDIZOLID PHOSPHATE; REG. NO/DATE: EU/1/15/991 20150325 |
| C0022 | France | ➤ Sign Up | PRODUCT NAME: DAPTOMYCINE; REGISTRATION NO/DATE: EU/1/05/328/001-002 20060119 |
| 2016 00004 | Denmark | ➤ Sign Up | PRODUCT NAME: CEFTOLOZAN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, SAERLIGT ET SVOVLSYRESALT; REG. NO/DATE: EU/1/15/1032/001 20150922 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
